Adam J. Gadzinski, MD, MS, on the Limitations of a Study Assessing the Impact of Telemedicine on Patient-Reported Outcomes

Video

Study results revealed the impact of a rurally focused telemedicine program on patient outcomes.

Study results presented at the Society of Urologic Oncology 21st Annual Meeting determined the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center (UWMC).

Through their research, the investigators determined that telemedicine provides a medium for cancer care delivery that eliminates the significant travel burden associated with in-person clinic appointments.

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and acting instructor of Urologic Oncology at the Urology Clinic at UWMC, explained the limitations of the study.

Transcription:

One of the limitations is that the survey was completed by roughly 42% of patients who were eligible for the survey. [Therefore], one limitation is [that] we don’t know what those other 58% of people thought; maybe they were the ones that hated telemedicine.

One of the other potential limitations is that we did not send the survey to patients who had what we called a “failed telemedicine visit”, or patients who were scheduled for telemedicine and then it didn't work and we had to call them on the phone. When we designed the study, we did not plan to include that group. We have kept track of who those patients were, but they did not systematically receive surveys. That’s another limitation and we don't know what the “failed telemedicine” patient-reported outcomes would be. I suspect they’d be a little less enthused about their visit.

We are planning to compare the patient characteristics of those who had a failed telemedicine visit versus a successful one. We haven’t done that yet, but that’s [on] one of our many to-do lists for the subsequent studies.

Recent Videos
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Related Content